1. Home
  2. ORGN vs ADAG Comparison

ORGN vs ADAG Comparison

Compare ORGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.12

Market Cap

109.4M

Sector

Industrials

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

BUY

Current Price

$3.96

Market Cap

146.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ORGN
ADAG
Founded
2008
2011
Country
United States
China
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.4M
146.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ORGN
ADAG
Price
$0.12
$3.96
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.00
AVG Volume (30 Days)
1.4M
198.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$49.18
$3,688.61
Revenue Next Year
$144.81
$17.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.33
52 Week High
$0.95
$4.58

Technical Indicators

Market Signals
Indicator
ORGN
ADAG
Relative Strength Index (RSI) 32.21 72.46
Support Level N/A $1.69
Resistance Level $0.18 N/A
Average True Range (ATR) 0.02 0.41
MACD -0.00 0.09
Stochastic Oscillator 13.55 77.26

Price Performance

Historical Comparison
ORGN
ADAG

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: